---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-268331"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:58:17.628918+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics announces atacicept Phase 3 data: 46% proteinuria reduction, 42% vs placebo (p<0.0001)

## Summary
- Atacicept achieved 46% reduction from baseline in UPCR at week 36; 42% reduction vs placebo (p<0.0001).
- Secondary endpoints: Gd-IgA1 reduced by 68%; hematuria resolved in 81% of participants with baseline hematuria.
- Safety profile favorable: serious adverse events 0.5% (atacicept) vs 5% (placebo); no deaths in either group.
- eGFR results not disclosed per FDA recommendation to sponsors of IgAN registrational trials.
- Data presented at ASN Kidney Week and simultaneously published in The New England Journal of Medicine.

## SEC filing metadata
- accession: 0001193125-25-268331
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312525268331/0001193125-25-268331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312525268331/d30094d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-268331
- JSON: https://secwatch.observer/filing/0001193125-25-268331.json
- Plain text: https://secwatch.observer/filing/0001193125-25-268331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.